Supplementary materials

Supplementary Table 1. Clinical and treatment variables based on the use of ticagrelor versus clopidogrel or prasugrel

	Ticagrelor	Clopidogrel or Prasugrel	*P*-value
Pre-PCI treatment, n/N (%)			
Heparin	98/290 (33.8)	117/240 (48.8)	<.001
Bivalirudin	18/292 (6.2)	32/240 (13.3)	.005
GP IIb/IIIa inhibitors	49/262 (18.7)	55/201 (27.4)	.027
ST resolution, n/N (%)	191/253 (75.5)	119/188 (63.3)	.006
Pre-PCI TIMI score, n/N (%)			.377
TIMI 0	182/292 (62.3)	148/221 (67.0)	
TIMI 1	72/292 (24.7)	41/221 (18.6)	
TIMI 2	24/292 (8.2)	18/221 (8.1)	
TIMI 3	14/292 (4.8)	14/221 (6.3)	
Post-PCI TIMI score, n/N (%)			<.001
TIMI 0	5/263 (1.9)	13/201 (6.5)	
TIMI 1	3/263 (1.1)	2/201 (1.0)	
TIMI 2	6/263 (2.3)	24/201 (11.9)	
TIMI 3	249/263 (94.7)	162/201 (80.6)	
Killip class, n/N (%)			.670
I	214/292 (73.3)	166/240 (69.2)	
II	33/292 (11.3)	33/240 (13.8)	
III	19/292 (6.5)	20/240 (8.3)	

IV	26/292 (8.9)	21/240 (8.8)	
Pre-PCI cardiac arrest, n/N (%)	38/292 (13.0)	18/240 (7.5)	.039
Culprit artery, n/N (%)			0.165
Left main	10/261 (3.8)	5/197 (2.5)	
Left anterior descending	122/261 (46.7)	85/197 (43.1)	
Circumflex	42/261 (16.1)	26/197 (13.2)	
Right coronary	76/261 (29.1)	77/197 (39.1)	
Bypass	11/261 (4.2)	4/197 (2.0)	
Diabetes, n/N (%)	54/290 (18.6)	56/235 (23.8)	.145
Dyslipidemia, n/N (%)	105/289 (36.3)	80/233 (34.3)	.635
Hypertension, n/N (%)	177/292 (60.6)	171/240 (71.3)	.010
Smoker, n/N(%)	135/292 (46.2)	95/237 (40.1)	.156
Cardiovascular disease, n/N (%)	26/290 (9.0)	30/235 (12.8)	.161
Number of vessels with significant disease, n/N(%)			.440
0	2/284	4/205	
1	105/284	70/205	
2	81/284	67/205	
3	96/284	64/205	

Abbreviations: GP, glycoprotein; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.

Supplementary Table 2. Analysis of 90-day mortality with ticagrelor versus no ticagrelor by propensity score quintile

	Hazard ratio	95% CI	*P*-value
Ticagrelor (no vs yes)	2.425	1.330–4.421	.004
Propensity score group			
1st vs 5th quintile	1.945	.872–4.337	.104
2nd vs 5th quintile	1.025	.427–2.461	.956
3rd vs 5th quintile	.591	.210–1.665	.320
4th vs 5th quintile	.486	.162–1.453	.196

Supplementary Figure 1. Kaplan–Meier curves of (A) 10-day and (B) 30-day cumulative survival with ticagrelor (n = 219) versus no ticagrelor (n = 200), based on propensity score-matched data.